# PBP1510

Source: https://onco.cc/drugs/pbp1510/  
OnCo record `pbp1510` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.

## Summary

PBP1510 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Prestige Biopharma Limited, in pancreatic ductal adenocarcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: PBP1510
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of PBP1510: https://clinicaltrials.gov/search?intr=PBP1510

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer](https://onco.cc/trials/nct05141149/)

---
JSON: https://onco.cc/api/v1/entities/pbp1510.json